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Currently the most suitable treatment for early squamous cell
carcinoma of the bronchus is photodynamic therapy (PDT). PDT
in early squamous carcinoma has demonstrated complete response
(CR) and cure (Furuse et al, 1993). However, many reports have
shown an almost 20% local recurrence after PDT (Edell et al,
1992; Furuse et al, 1993; Sutedja et al, 1994), and so it is important
to determine the factors which influence the onset of local
reccurence.
One of the factors could be inherent tumour cell resistance. Pass
(1993) showed that if there is regrowth of tumour after PDT, it
usually occurs at the edge of the tumour and the regrowth could be
due to inherent tumour cell resistance, hypoxia, inadequate drug
uptake, or inadequate drug and/or light dose concentration.
The effect of PDT is thought to be non-specific damage due to
the production of single oxygen. Recent studies, though, indicate
that PDT can induce apoptosis both in vivo and in vitro. Agarwal
et al (1991, 1993) showed that PDT stimulates phospholipases on
cell membranes, and initiates apoptosis in mouse lymphoma cells.
In addition, they demonstrated that PDT can cause increased
synthesis of ceramide, and that ceramide production is linked to
apoptosis in PDT treated L5178Y-R cells (Separovic et al, 1997).
Though PDT photo-oxidizes cellular targets, the control systems
and mechanisms remain largely unknown. Fisher et al (1997)
reported that photosensitivity was increased in HL-60 cells
expressing wild-type p53, and that photosensitizer-mediated
oxidative stress can induce apoptosis through a p53-independent
mechanism. The bcl-2-expressing cell was also reported to be 
relatively resistant to PDT in Chinese ovary cell (He et al, 1996).
Bcl-2, a proto-oncogene which is expressed in a variety of
malignant tumours, works as an inhibitor of apoptosis. The p53 is
a tumour suppressor gene, and is the most commonly mutated
gene occurring in cancer. Because the bcl-2 expression is nega-
tively regulated by the wild-type p53, the p53 gene mutations
inhibit apoptosis as well as cause a loss of tumour suppressor func-
tion. The mutated p53 is reported to be detected by immunohisto-
chemical staining (Nishio et al, 1996).
In this paper, the clinical outcome of patients in early stage
bronchogenic carcinoma treated with PDT was studied. The bcl-2
and p53 protein in bronchoscopic specimens before treatment
were examined immunohistochemically. Whether expression of
bcl-2 and p53 protein can be predictive of local recurrence after
PDT was assessed.
MATERIALS AND METHODS
Patients and therapy
From 1983 to 1997, 50 patients with 59 early squamous cell carci-
noma of the bronchus received PDT in this institute. Patient char-
acteristics are shown in Table 1. The age of the patients ranged
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(CR) and cure. However, local recurrence after PDT develops frequently even after complete remission. Because the effect of PDT had been
reported to depend on apoptosis, and apoptosis is inhibited by bcl-2 protein, the relationship between the expression of bcl-2 protein and local
recurrence after PDT was examined immunohistochemically. From 1983 to 1997, 50 patients with 59 early squamous cell carcinoma of the
bronchus received PDT, and a CR was obtained in 43 lesions (72.8%). As there was no recurrence among tumours that were disease-free for
more than 2 years, in this study the tumours were defined as cured when recurrence did not occur 2 years subsequent to the receiving of PDT.
Of these CR lesions, 31 carcinomas (53.4%) resulted in a cure. Bcl-2 immunoreactivity was detected in 23 tumours (46.9%) and p53
immunoreactivity was detected in 22 tumours (44.9%). When all tumours were divided into either a large tumour with a longitudinal tumour
length of 10 mm or more, or a small tumour with a length of less than 10 mm, the large tumour expressed more bcl-2 protein than the small
tumour (P = 0.0155). The degree of bcl-2 expression was significantly related with tumour size (P = 0.0155). The expression of bcl-2 and p53
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Correspondence to: T Kawaguchifrom 48 to 80 years old (median 68 years); 46 were male and four
were female. According to the TNM classification, nine cases
were TisN0M0 and 50 cases T1N0M0 (Mountain, 1986). The
length of longitudinal tumour extent on the bronchial surface was
estimated by a bronchoscopist. This measurement was estimated
using open-biopsy forceps of known diameter or a special
bronchial scale, and photographs were taken at the same time.
Twenty-eight cases underwent PDT by excimer dye laser, 25 cases
were treated using argon dye laser and six underwent PDT with
YAG OPO laser.
PDT was performed using a flexible fibrebronchoscope, through
which a laser beam was delivered to the lesions. All procedures
were performed under local anaesthesia. All patients received 3 mg
kg–1 photofrin I or 2 mg kg–1 photofrin II intravenously, 48 h before
PDT. Treatment energies ranged from 100 to 300 J cm–2 (median
200 J cm–2) in the excimer dye laser and YAG-OPO laser, and from
30 to 810 J cm–2 (median 290 J cm–2) in the argon dye.
Of the tumours treated with PDT, 43 lesions (72.8%) obtained a
CR. A CR was defined as no demonstrable tumour by biopsy
and/or brushing, and no tumour visible on chest roentgenogram for
at least 4 weeks.
Extended, long follow-up results of the lesions treated with PDT
have been studied. Median follow-up time after PDT was 7 years
and 2 months with a range of 3 months to 14 years. One CR tumour
was lost in follow-up. Of 42 CR tumours, 11 lesions recurred
locally within 2 years follow-up. There was no recurrence among
tumours which were disease-free for more than 2 years. Therefore,
in this study, the tumour was defined to be cured if there was no
recurrence after 2 years subsequent to PDT. As a result, 31 lesions
(53.4%) obtained a cure after a single course of PDT.
Tumour biopsies
Forty-nine biopsy specimens were collected from 59 tumours. Ten
lesions were excluded because they were so small as to be unsuit-
able for immunohistochemical examination. These specimens
were fixed in 10% formaldehyde solution and embedded in
paraffin. Four-micrometre-thick sections were cut and mounted on
glass slides.
Immunohistochemical staining
Immunohistochemical studies were performed by the strepta-
vidin–biotin method. Sections were deparaffinized in xylene and
absolute alcohol and autoclaved at 121°C with distilled water for
20 min. After cooling 10% rabbit serum was plased on the slides to
reduce background staining. For bcl-2 immunostaining, specimens
were incubated overnight with a 1:20 dilution of an anti-bcl-2
monoclonal antibody (Dako A/S, Glostrup, Denmark) at room
temperature. For p53 immunostaining specimens were incubated
for an hour with a 1:50 dilution of an anti-p53 monoclonal anti-
body, DO-7 (Dako A/S, Glostrup, Denmark) at room temperature.
The sections were then incubated with biotinylated donkey anti-
mouse immunoglobulin G for 30 min. The slides were treated with
streptavidin–peroxidase for 30 min, reacted in phosphate-buffered
saline (PBS) containing diaminobenzidine, counterstained with
haematoxylin and mounted.
A tumour was considered to be immunopositive for bcl-2 when
the number of cells with stained cytoplasm exceeded 5%, and
immunopositive for p53 when the number of cells with stained
nuclei exceeded 10%. According to Nishio (1996), a 10% cutoff
value reliably indicates the presence of mutated p53.
Slides were interpreted by two investigators (TK and SY) who
reached agreement without prior knowledge of the clinical
outcome.
Statistical analysis
The relationship between the expression of bcl-2, p53 protein and
clinical data was examined by univariate analysis. Pretreatment
variables, including expression of bcl-2 and p53 protein, were
investigated for any possible relationship to cure and local recur-
rence after PDT, first by univariate analysis, and subsequently by
application of a multiple regression model. The univariate analysis
was based on 2 ´ 2 tables, and differences were tested by use of the
c2 test or Fisher’s exact test.
RESULTS
The bcl-2 immunoreactivity was localized in the cytoplasm of
neoplastic cells and bcl-2 immunopositivity was detected in 23
tumours (46.9%); p53 immunoreactivity was confined to the
nuclei of neoplastic cells and p53 immunopositivity was detected
in 22 tumours (44.9%) (Figures 1 and 2).
The relationship between the expression of bcl-2, p53 protein
and clinical data is shown in Table 2. When all the tumours were
divided by median value of age (> 68 vs 68³), T status in TNM
staging (Tis vs T1) and tumour morphology (superficial type vs
non-superficial type), there was no significant relationship
between the expression of bcl-2, p53 protein and these variables.
When the tumours were divided into a large tumour group with a
longitudinal tumour length of 10 mm or more, and a small tumour
group with a length of less than 10 mm, bcl-2 expression was
found in nine of 14 (64.3%) tumours in the large and eight of 33
(24.2%) tumours in the small tumour group. This difference was
statistically significant (P = 0.0155).
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Table 1 Patient characteristics of 50 patients with 59 carcinomas
Age
Median 68
Range 48–80
Sex (male/female) 46/4
Stage (no. of carcinomas)
TisN0M0 9
T1n0m0 50
Location of tumour
Trachea 6
Main bronchus 0
Lobar bronchus 16
Segmental bronchus 32
Subsegmental bronchus 5
Tumour morphology
Superficial type 34
Nodular type 15
Polypoid type 10
Estimated length of tumour (mm)
>20 4
20– >10 11
≤10 44
Distal tumour margin
Clearly visible 45
Not clearly visible 14The follow-up outcome of PDT and clinicopathological data
were examined. As mentioned above, the 31 carcinomas were
defined as cured. The relationship between the cure due to PDT
and pretreatment variables, including expression of bcl-2 and p53
protein, are shown in Table 3. Expression of bcl-2 and p53 protein
was not associated with the cure after PDT. Visibility of the distal
tumour margin, tumour location and tumour morphology also
showed no association with the cure. Both the tumour length and T
status in TNM staging were significantly related to the cure by
univariate analysis. The factors influencing the cure due to PDT
were examined by multivariate analysis. As shown in Table 4,
only T status in TNM staging was significantly related to the cure.
Moreover, the factors considered to influence the local recur-
rence after PDT were evaluated. Because one CR tumour was lost
in follow-up, 42 CR tumours were examined. As described above,
11 lesions recurred locally. The results of the relationship between
local recurrence and clinicopathological data are shown in Table 5.
T status in TNM staging was significantly associated with the
local recurrence according to univariate analysis (P = 0.0320);
expression of bcl-2 and p53 protein was not associated with local
recurrence. The results of the multivariate analysis of the same 42
CR lesions are shown in Table 6. T status in TNM staging was 
also significantly associated with local reccurence after PDT 
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Figure 1 Immunohistochemical staining of bcl-2 protein in early squamous
cell carcinoma of the bronchus. The immunoreactivity was localized in the
cytoplasm of neoplastic cells
Figure 2 Immunohistochemical staining of p53 protein in early squamous
cell carcinoma of the bronchus. The immunoreactivity was confined to the
nuclei of neoplastic cells
Table 2 Relationship between expression of bcl-2, p53 and clinical data
Variable bcl-2 p53
Negative Positive P Negative Positive P
Age
>68 15 9 0.9248 13 11 0.9897
³68 15 7 11 11
T status in TNM stage
Tis 6 2 0.8229 4 4 0.8433
T1 26 15 22 19
Tumour morphology
Superficial type 20 9 0.5746 17 12 0.2813
Non-superficial type 12 8 9 11
Length of tumour
>10 5 9 0.0155 10 5 0.3382
³10 25 8 16 18
Table 3 Relationship between the cure and clinicopathological data;
Results of univariate analysis
Cure
(–) (+) P
bcl-2
(–) 15 17 0.3735
(+) 11 6
p53
(–) 16 10 0.4994
(+) 11 12
Length of tumour
>10 12 3 0.0066
10³ 15 28
T status in TNM stage
Tis 0 9 0.0073
T1 27 22
Tumour margin
Clear 17 27 0.0665
Not clear 10 4
Tumour location
Distal to segmental bronchus 19 17 0.2239
Proximal to lobar bronchus 8 14
Tumour morphology
Superficial type 17 15 0.3334
Non-superficial type 10 16(P = 0.008). The products of bcl-2 and p53, tumour length, distal
tumour margin, tumour location and tumour morphology were not
associated with the local recurrence after PDT.
DISCUSSION
PDT is an effective treatment modality in a variety of solid cancers
due to the lack of cumulative toxicity and slight mucosal damage
(Kawaguchi et al, 1998). PDT in early-stage bronchogenic carci-
noma has been shown to result in 74–85% CR. An important factor
in regulating CR was longitudinal tumour extent. On the other
hand, tumour location, tumour morphology and distal tumour
margin were not important factors. Indeed, an excellent 97.8% CR
rate could be obtained with limited longitudinal extent (≤ 1 cm)
(Furuse et al, 1993). With regard to long-term follow-up in patients
with centrally located early-stage bronchogenic carcinoma,
complete cure cases treated with PDT were reported (Kato et al,
1986). Cortese (1997) showed that nine of 21 patients (43%) with
early-stage squamous cell carcinoma who were candidates for
PDT could be spared surgical resection, and the mean duration of
follow-up for these nine patients was 68 months. In this study there
was no recurrence among patients who were disease-free for more
than 2 years. The 31 patients (53.4%) were considered to be cured
if there was no recurrence 2 years post-PDT. Therefore, PDT could
be considered an effective method to treat and cure an early-stage
bronchogenic carcinoma. However, it is still problematic that 11
local recurrences in 42 CR lesions have occurred within 2 years
after PDT in our study. Several reports also showed that there was
almost 20% local recurrence rate after PDT (Edell et al, 1992;
Furuse et al, 1993; Sutedja et al, 1994). To establish the treatment
of PDT for early-stage bronchogenic carcinoma, it is important to
determine the factors that influence the onset of local recurrence.
There are many possible reasons for local recurrence after PDT.
In this study, we focused on the inherent tumour cell resistance to
PDT, because recent studies showed that the anti-tumour effect of
PDT has depended on apoptosis (Agarwal et al, 1991, 1993).
Oncoproteins such as bcl-2 or p53, which regulate apoptosis, have
also been documented to influence the outcome of PDT in vitro
(He et al, 1996; Fisher et al, 1997). Although there are many clin-
ical reports on the impact of bcl-2 or p53 protein expression on the
response of chemotherapy and radiotherapy, little clinical data
have been available concerning the relationships between onco-
protein and PDT. Therefore, using immunohistochemical tech-
niques, we retrospectively studied the effect of oncoprotein on the
cure rate and local recurrence after PDT.
Bcl-2 immunoreactivity was detected in 23 tumours (46.9%)
and p53 immunoreactivity detected in 22 tumours (44.9%). When
the tumour length was divided into two groups, 10 mm or more or
less than 10 mm in length, the larger tumours expressed the bcl-2
protein more significantly (P = 0.0155); the degree of relationship
of bcl-2 expression to tumour size was significant (P = 0.0155).
Expression of bcl-2 protein can be observed at a very early stage in
the development of lung cancer. Walker (1995) showed that 
aberrant bcl-2 expression was identified in mild dysplasia using
immunohistochemical analysis, and that it correlated with an
increasing grade of dysplasia. Koukourakis et al (1997) showed
that a strong inverse relationship was found between the bcl-2
expression and tumor angiogenesis. They suggested that bcl-2
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Table 4 Factors influencing the cure due to PDT; results of logistic
regression analysis
Variable b s.e.m. P
bcl-2 –0.060 0.165 0.707
(–) vs (+)
p53 0.080 0.149 0.594
(–) vs (+)
Length of tumour –0.152 0.190 0.393
(> 10 vs 10³)
T status in TNM stage –0.361 0.190 0.0167
(Tis vs T1)
Tumour margin –0.044 0.176 0.784
(Clear vs not clear)
Tumour location –0.178 0.149 0.218
(Distal to segmental bronchus vs proximal 
to lobar bronchus)
Tumour morphology 0.146 0.148 0.332
(Superficial type vs non-superficial type)
Table 5 Relationship between local recurrence and clinicopathological data
in 42 CR lesions; Results of univariate analysis
Local recurrence
(–) (+) P
bcl-2
(–) 17 8 0.9556
(+) 6 4
p53
(–) 10 6 0.9157
(+) 12 6
Length of tumour
>10 3 1 0.6777
10³ 27 11
T status in TNM stage
Tis 9 0 0.0320
T1 21 12
Tumour margin
Clear 26 10 0.7803
Not clear 4 2
Tumour location
Distal to segmental bronchus 16 10 0.0705
Proxymal to lobar bronchus 14 2
Tumour morphology
Superficial type 14 9 0.1166
Non-superficial type 15 3
Table 6 Factors influencing the local recurrence after PDT (42 CR lesions);
results of logistic regression analysis
Variable b s.e.m. P
bcl-2 –0.102 0.184 0.557
(–) vs (+)
p53 0.073 0.182 0.703
(–) vs (+)
Length of tumour 0.144 0.351 0.550
(>10 vs 10³)
T status in TNM stage –0.481 0.189 0.008
(Tis vs T1)
Tumour margin –0.081 0.245 0.684
(Clear vs not clear)
Tumour location –0.273 0.176 0.127
(Distal to segmental bronchus vs proximal 
to lobar bronchus)
Tumour morphology 0.172 0.179 0.353
(Superficial type vs non-superficial type)positive tumours are present at an early stage of progression, with
loss of bcl-2 expression a relatively late event in the pathogenesis
of the lung cancer. Early-stage bronchogenic carcinoma in this
study, which has little or no potential to metastasize, may be
evident at an early stage of progression. Therefore, the degree of
bcl-2 expression, as well as the degree of bronchial dysplasia,
might be significantly related to tumour size (P = 0.0155).
In our study, the expression of bcl-2 and p53 protein was not
documented as a poor prognostic indicator of PDT. Tumour
volume, estimated by T status in TNM staging and tumour length,
was the significant indicator of the cure according to univariate
analysis. By mutivariate analysis, only T status in TNM staging
was the single significant indicator of the cure. In addition, with
regard to the local recurrence after PDT, only T status in TNM
staging was also significantly associated with it. Since the expres-
sion of bcl-2 and p53 protein did not influence the prognosis of
PDT, this treatment may not be associated with apoptosis in the
clinical setting as seen in vitro. Indeed, He et al (1994) described
that apoptosis induced by PDT in vitro depends on the kind of
photosensitizer and cell line. Luo (1997) showed that the mode of
cell death can be shifted from an apoptotic to a necrotic response
as a function of the PDT dose. Higher light doses yielded progres-
sively more membrane photodamage and inhibited the apoptotic
response. In a clinical setting, it is possible that higher light doses
and higher photosensitizer concentration are achieved in some
cases, because subepitheial fibrosis was found in histological
examination of clinical PDT (Kawaguchi et al, 1998). In addition,
the tumour vessel is considered to be an important target of PDT
(Star et al, 1986). Although vascular damage can also lead to
apoptosis, these relationships need further investigation.
Our study showed that the success of PDT is related to the
tumour volume, especially T status in TNM staging, and the clin-
ical T status could reflect tumour depth. Although bronchoscopic
techniques have been well developed, there has been little
endeavour to estimate the degree of tumour depth. Now new tech-
niques such as ultrasonography may improve the assessment of
tumour depth. While tumour length is thought to be an important
indicator of cure by PDT, our multivariate analysis using factors
such as the expression of bcl-2 and p53 protein, tumour length, T
status, distal tumour margin, tumour location and tumour
morphology did not show that tumour length is a significant indi-
cator. We attempted multivariate analysis using the same factors
except the expression of the bcl-2 and p53 protein, revealing that
both T status and tumour length were significant indicators of cure
by PDT (data is not shown). The expression of bcl-2 and p53
protein may be a noisy factor. Although one of the features of
centrally-located early stage bronchogenic carcinoma is the diffi-
culty of identifying the tumour (Usuda et al, 1993), an exact
assessment of tumour spread is important. Light-induced fluores-
cence endoscope (LIFE), a new technique, may improve the
assessment of the tumour spread. Further study is warranted,
including endobronchial ultrasonography.
The other cause of local recurrence after PDT may be light
insufficiency (Furuse et al, 1993; Sutedja et al, 1994, 1996).
Indeed, the light dose in PDT protocols is more or less empirical.
These illumination protocols using fixed light doses do not take
into account the different concentrations of photosensitizers in the
tissue concerned, as has been shown by Braichotte (1996). To raise
the cure rate and reduce the local recurrence rate of PDT, it may be
important to identify optimal PDT illumination.
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